Drug Trial Radar · NCT01113229
Combined Use of Oxytocin and Misoprostol in the Prevention of Post Partum Haemorrhage
Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,721
Actual
Start
Mar 2010
Primary completion
Jul 2014
Study completion Dec 2014
Sponsor
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- URC-CIC Paris Descartes Necker Cochin
- First posted
- Apr 29, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- Female only, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To demonstrate that the combined used of oxytocin and misoprostol prevent from post partum haemorrhage better than oxytocin alone, following vaginal birth at 36 to 42 weeks.
Conditions
- Hemorrhage; Complicating Delivery
Interventions
MisoprostolDrug
two misoprostol tablets taken orally (400µg)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of post partum hemorrhage > 500mL in 1 hourTime frame: 1 HOUR
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chi Poissy St Germain
Poissy, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.